Thyrocare Technologies Ltd - 539871 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (LODR) Regulation, 2015, please find enclosed disclosure of related party transactions for the half year ended March 31, 2022. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find attached herewith copy of the transcript of the Conference Call held on Friday, May 06, 2022, and the same is also available at website of the Company (www.thyrocare.com) pursuant to the provisions of Schedule III, Part A, Clause 15(b)(2). Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Further to our letter dated 05-05-2022, we wish to inform that the post 2022 financial results conference call with the analysts / investors was held on Friday, the 6th May 2022. The audio recording of the same is available at our website, and can be accessed by using the link provided in the enclosed sheet . Thyrocare Technologies Ltd - 539871 - Joining Of Mr. Rahul Guha As The Managing Director & Chief Executive Officer - Intimation Under Regulation 30 Read With Part A To Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Thyrocare Technologies Limited has informed the Exchange about appointment of Mr. Rahul Guha as Managing Director and Chief Executive Officer of the company w.e.f. 04-May-2022.Mr. Rahul Guha will also function as the Managing Director & CEO of Nueclear Healthcare Limited, our wholly owned subsidiary. Mr. Dharmil Sheth, who was appointed as the Managing Director for the interim period to comply with the provisions of Sec. 203 (4) of the Companies Act, 2013, has demitted office effective from Wednesday, May 04, 2022 and will continue to be a Non-Executive, Non-Independent Director of the Company. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Further to our letter dated 03-05-2022, intimating that a conference call for the Indian and overseas analysts has been arranged by our management to discuss the Company's financial results for Quarter / Whole year ended March 31, 2022, on Friday, May 06, 2022 at 04.00 p.m. local time Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
we wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company's financial results for Quarter / Whole year ended March 31, 2022, on Friday, May 06, 2022 at 04.00 p.m. local time. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Audited financial results for the quarter / year ended 31-03-2022 - pursuant to Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Q4FY22 Quarterly Result Announced for Thyrocare Technologies Ltd.
Healthcare Services firm Thyrocare Technologies declares Q4FY22 result: Revenue from operations of Rs. 562 Crore, grown by 18% YoY. Revenue for the final quarter of the year of Rs. 123 Crore, grown by 12% in sequential quarters mainly with revival of the base non covid business. Revenue from COVID business was flat in sequential quarters despite of 3rd wave in January. Non Covid business however revived significantly and surpassed the pre-COVID business. Continued focus on B2B business enabled us to garner lost volumes. Revenue and volumes for the month of March were all time high Gross margin for the year improved mainly on account of reduction in the covid reagent/ consumables, however to enable growth aggressive prices are offered in the last quarter on routine non aarogyam tests and certain aarogyam profiles that has lead to impact on Q4 gross margins which shall settle down in the coming period. Absolute EBITDA of Rs. 231 crore, grown by 35% YoY, mainly on account of better EBITDA margins on account of lower reagent/ consumable and operations cost in Government COVID business. The EBITDA margin at 41% for the year were tampered down in the last two quarters mainly on account of impact on the topline due to erosion of high margin government contract business, aggressive discounts to the network on some routine tests/ profiles to revive the business, spendings on manpower in particular growth teams to sustain growth and infrastructure to improve turnaround time to the patients. 4.40 million COVID RTPCR tests were performed in the year, though despite 3 rd wave in January only 0.41 million were performed in the last quarter, thereby the focus is now shifted to non COVID segment. Total 21.07 million samples (including COVID) sourced from 16.32 million patients (including COVID) were processed during current year. 110.30 million tests were processed in the current year that includes standalone tests, COVID tests and tests included in the preventive care Aarogyam profiles. Pathology business grew by 12% in sequential quarter and yearly by 18%. Growth in the current quarter was mainly on account of revival of B2B non COVID business Radiology business accounted for about 5% of reported consolidated revenue of Thyrocare Group revived significantly after complete shut down for couple of months in covid and thereafter out of the impact of lockdowns, posting 34% YOY growth in the current year Consolidated annual revenue of the group grew by 19% YOY, with positive signs of revival in non covid business. COVID business significantly eroded in last two quarters and radiology business growing at pre COVID level. Result PDF
Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Investor Presentation
Presentation on Audited Financial Results for the quarter / whole year ended 31-03-2022